COGT · Cogent Biosciences, Inc.
$39.76
+0.57% last session
End-of-day data · updated 2026-07-28
Market cap
$7B
Enterprise value
$6B
Trailing P/E
—
Forward P/E
-42.8
Dividend yield
—
Beta
0.34
Avg volume
2M
Employees
0K
2D change
1.71%
5D change
0.50%
10D change
3.48%
30D change
6.14%
60D change
15.68%
MTD change
5.09%
YTD change
13.85%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — COGT
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-05-29
Latest call per bank · past 12 months
JP Morgan
Overweight$67.00
+68.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-05-29 | Wedbush | Reiterates | Outperform | $55.00 |
| 2026-05-06 | HC Wainwright & Co. | Maintains | Buy | $52.00 → $55.00 |
| 2026-03-17 | Wedbush | Reiterates | Outperform | $55.00 |
| 2026-02-18 | Piper Sandler | Maintains | Overweight | $39.00 → $52.00 |
| 2026-01-21 | Wedbush | Reiterates | Outperform | $55.00 |
| 2026-01-06 | HC Wainwright & Co. | Maintains | Buy | $50.00 → $52.00 |
| 2025-12-19 | JP Morgan | Maintains | Overweight | $65.00 → $67.00 |
| 2025-12-08 | Needham | Reiterates | Hold | $0.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 63 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 13.3% above the 50-day MA ($35.90).
- Price vs 200-day MA: Trading 18.7% above the 200-day MA ($34.26).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is positive (+0.01) — short-term momentum is improving.
- 52-week range: Price is within 5% of the 52-week high ($42.11).
COGT Price Chart
Loading chart for COGT…
Fundamentals
About Cogent Biosciences, Inc.
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.